Madrigal Pharmaceuticals (MDGL) Short term Debt (2010 - 2016)

Madrigal Pharmaceuticals (MDGL) has 7 years of Short term Debt data on file, last reported at $10000.0 in Q2 2016.

• Quarterly Short term Debt fell 99.89% year-over-year to $10000.0 in Q2 2016, while the trailing twelve-month figure through Jun 2016 was $10000.0 (down 99.89% YoY) and the FY2015 annual result came in at $4.6 million, down 50.0% from the prior year.
• Short term Debt eased to $10000.0 in Q2 2016 per MDGL's latest filing, from $2.3 million in the prior quarter.
• Across five years, Short term Debt topped out at $9.5 million in Q4 2013 and bottomed at $10000.0 in Q2 2016.
• The 5-year median for Short term Debt is $7.9 million (2012), against an average of $6.9 million.
• The widest annual swing landed in 2014, when Short term Debt surged 200.58%; it then tumbled 99.89% in 2016.
• Tracing MDGL's Short term Debt over 5 years: stood at $7.9 million in 2012, then rose by 19.27% to $9.5 million in 2013, then slipped by 2.51% to $9.2 million in 2014, then tumbled by 50.0% to $4.6 million in 2015, then tumbled by 99.78% to $10000.0 in 2016.
• Per Business Quant, the three latest MDGL Short term Debt figures stand at $10000.0 (Q2 2016), $2.3 million (Q1 2016), and $4.6 million (Q4 2015).

Peer Comparison